Cempra, Inc. to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on Feb. 27, 2014 CHAPEL HILL, N.C., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will report fourth quarter and full year 2013 financial results and provide a business update after the close of U.S. financial markets on Feb. 27, 2014. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EST,Feb. 27, 2014. The conference call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers. Please specify to the operator that you would like to join the "Cempra, Inc., Fourth Quarter and Full Year 2013 Financial Results Call, conference ID#: 2739816." The conference call will be webcast live under the investor relations section ofCempra's website atwww.cempra.com, and will be archived there for 30 days following the call. Please visitCempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. AboutCempra, Inc. Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP) and is licensed to strategic partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product candidate, which is currently in a Phase 2 clinical trial for prosthetic joint infections. Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com. CONTACT: Investor and Media Contacts: Robert E. Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 Robert.email@example.com Andreas Marathovouniotis Russo Partners, LLC (212) 845-4235 Andreas.firstname.lastname@example.org
Cempra, Inc. to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast
Press spacebar to pause and continue. Press esc to stop.